Holen Sie sich die Stockscreener-App
294.60
2.00%
5.775
Handel nachbörslich:
294.60
0.005
+0.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Bank of America Corp DE Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock - moomoo.com
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares - MarketBeat
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock - MarketBeat
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares - Investing.com
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares By Investing.com - Investing.com UK
Ligand Pharmaceuticals (LGND) director exercises options and sells 7,138 shares - Stock Titan
LGND Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners - MarketBeat
Stifel reiterates Buy on Ligand Pharma stock, $332 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run - Yahoo Finance
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced? - Yahoo Finance
Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals - Stock Titan
Ligand (LGND) Q2 2026 Earnings Call Transcript - The Globe and Mail
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC SEC Filing (Aug 12, 2026) - Stock Titan
Ligand (NASDAQ: LGND) holder Jason Haas files Form 144 for stock sale - Stock Titan
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390 - moomoo.com
Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
LGND: XOMA Acquisition Closed - Smartkarma
Weekly Recap: Q2 revenue, royalty growth and $700M convertible notes - TradingView
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results - MarketBeat
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370 - moomoo.com
California State Teachers Retirement System Acquires 4,987 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND SWOT Analysis: Strong Revenue Growth Amidst Valuation Conce - GuruFocus
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $370 - Moomoo
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345 - Moomoo
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $326 - Moomoo
Ligand Pharmaceuticals (LGND) Releases Q2 2026 Earnings: Revenue Declines but EPS Jumps - Quiver Quantitative
LGND Maintained by RBC Capital -- Price Target Raised to $345 - GuruFocus
Ligand Pharmaceuticals 2Q 2026: Revenue $63.69M, EPS $2.22— 10-Q Summary - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) lifts Q2 net income to 48,508 - Stock Titan
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Ligand Pharmaceuticals, Inc. : H.c. Wainwrigh - moomoo.com
RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating - marketscreener.com
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
LIGAND PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $358 FROM $289 - Bitget
Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highli - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $358.00 Price Target at HC Wainwright - MarketBeat
Earnings call transcript: Ligand beats Q2 2026 estimates as shares rise - Investing.com Canada
Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Yahoo Finance
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $358 - GuruFocus
Ligand Pharmaceuticals Q2 Earnings Call Highlights - TradingView
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $343.3, Implies 13% Upside - TradingView
Ligand Pharmaceuticals Incorporated 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LGND) 2026-08-06 - Seeking Alpha
Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2026 Earnings Guidance - MarketBeat
Is Ligand Pharmaceuticals (LGND) Trading at 69.1% Overvaluation - GuruFocus
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed - Moomoo
Q2 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
(LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21 - marketscreener.com
Ligand Pharmaceuticals Q2 revenue rises on royalty growth - TradingView
Ligand: Q2 Earnings Snapshot - Yahoo Finance
Ligand reports Q2 2026: Revenue $63.7M, Royalties $48.0M, GAAP EPS $2.22, Adjusted EPS $2.37 - TradingView
Ligand Reports Second Quarter 2026 Financial Results - marketscreener.com
BRIEF-Ligand Pharmaceuticals Q2 EPS USD 2.22 - TradingView
Press Release: Ligand Reports Second Quarter 2026 Financial Results - Moomoo
Segall Bryant & Hamill LLC Takes $1.34 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Adds More Than 120 Royalty Assets in XOMA Acquisition - Stock Titan
Moody National Bank Trust Division Acquires Shares of 12,147 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares - MarketBeat
Public Employees Retirement System of Ohio Sells 5,600 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):